Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients

被引：0
|
作者：
Weichenthal, Michael
Chiarion-Sileni, Vanna
Hauschild, Axel
Del Bianco, Paola
Trefzer, Uwe
Guida, Michele
Enk, Alexander
Romanini, Antonella
Loquai, Carmen
Ridolfi, Ruggero
Schadendorf, Dirk
Mandala, Mario
Koller, Josef
Silvestri, Barbara
Gogas, Helen
Medici, Michele
Dummer, Reinhard
De Salvo, Gian Luca
Mohr, Peter
机构：
[1] Univ Dept Dermatol, Kiel, Germany
[2] Ist Oncol Veneto, Melanoma & Skin Canc Unit, Padua, Italy
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Clin Trials & Biostat Unit, Padua, Italy
[5] Charite, Melanoma Ctr, D-13353 Berlin, Germany
[6] Ist Oncol, Bari, Italy
[7] Heidelberg Univ, Hautklin, Heidelberg, Germany
[8] Santa Chiara Univ Hosp Pisa, Pisa, Italy
[9] Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany
[10] IRST IRCCS, Immunotherapy & Somat Cell Therapy Lab, Meldola, Italy
[11] Univ Klinikum Essen, Essen, Germany
[12] Papa Giovanni XXIII, Div Med Oncol, Unit Clin & Translat Res, Dept Hematol & Oncol, Bergamo, Italy
[13] Landesklin Dermatol, Salzburg, Austria
[14] Gen Hosp, Noale, Italy
[15] Hellen Cooperat Oncol Grp HeCOG, Athens, Greece
[16] Osped Angelo, Mestre Venice, Italy
[17] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[18] Elbeklinikum Buxtehude, Buxtehude, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20028
引用
收藏
页数：1
相关论文
共 33 条
  • [1] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Schadendorf, Dirk
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Anette
    Schneider, Lars
    Podda, Maurizio
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b)
    Mohr, P.
    Hauschild, A.
    Rass, K.
    Trefzer, U.
    Enk, A.
    Haalck, T.
    Koller, J.
    Gutzmer, R.
    Kuechler, T.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.) [ISRCTN75125874]
    Chiarion-Sileni, V
    Del Bianco, P
    Romanini, A
    Guida, M
    Paccagnella, A
    Dalla Palma, M
    Naglieri, E
    Ridolfi, R
    Silvestri, B
    Michiara, M
    De Salvo, GL
    [J]. BMC CANCER, 2006, 6 (1)
  • [6] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
    Vanna Chiarion-Sileni
    Paola Del Bianco
    Antonella Romanini
    Michele Guida
    Adriano Paccagnella
    Maurizio Dalla Palma
    Emanuele Naglieri
    Ruggero Ridolfi
    Barbara Silvestri
    Maria Michiara
    Gian Luca De Salvo
    [J]. BMC Cancer, 6
  • [7] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [8] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [9] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [10] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
1234